LPL Financial LLC Increases Position in Certara, Inc. (NASDAQ:CERT)

LPL Financial LLC increased its stake in shares of Certara, Inc. (NASDAQ:CERT) by 17.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 112,624 shares of the company’s stock after buying an additional 16,586 shares during the period. LPL Financial LLC owned about 0.07% of Certara worth $1,288,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in CERT. Kopion Asset Management LLC lifted its position in shares of Certara by 46.0% during the 4th quarter. Kopion Asset Management LLC now owns 555,643 shares of the company’s stock valued at $5,918,000 after acquiring an additional 175,005 shares during the period. Principal Financial Group Inc. raised its holdings in Certara by 3.1% during the fourth quarter. Principal Financial Group Inc. now owns 531,445 shares of the company’s stock worth $5,660,000 after purchasing an additional 15,739 shares during the last quarter. Vontobel Holding Ltd. purchased a new stake in Certara during the fourth quarter worth $1,295,000. Barclays PLC grew its holdings in Certara by 198.3% in the third quarter. Barclays PLC now owns 70,525 shares of the company’s stock valued at $825,000 after purchasing an additional 46,880 shares during the last quarter. Finally, Proficio Capital Partners LLC purchased a new position in shares of Certara in the fourth quarter valued at $148,000. 73.96% of the stock is currently owned by institutional investors and hedge funds.

Certara Price Performance

Shares of NASDAQ:CERT opened at $14.15 on Friday. The business has a fifty day simple moving average of $11.62 and a 200-day simple moving average of $11.46. Certara, Inc. has a 52 week low of $8.64 and a 52 week high of $17.94. The company has a market cap of $2.28 billion, a P/E ratio of -70.75, a P/E/G ratio of 9.29 and a beta of 1.64. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28.

Analysts Set New Price Targets

CERT has been the topic of a number of research reports. Robert W. Baird increased their price objective on shares of Certara from $9.00 to $13.00 and gave the company a “neutral” rating in a research note on Friday, April 11th. Barclays lowered their price target on shares of Certara from $13.00 to $11.00 and set an “equal weight” rating on the stock in a research report on Thursday, April 10th. Stephens restated an “overweight” rating and set a $17.00 price objective on shares of Certara in a research report on Thursday, February 27th. William Blair reiterated a “market perform” rating on shares of Certara in a report on Thursday, February 27th. Finally, TD Cowen assumed coverage on Certara in a research report on Thursday, February 27th. They issued a “buy” rating and a $16.00 price objective on the stock. Four analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $15.17.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.